- Sulagna Bhattacharya, Chief Executive Officer, to deliver corporate presentation on Monday, September 14, 2026
NEW YORK, Sept. 11, 2026 /PRNewswire/ — New York, September 11, 2026 — Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that Sulagna Bhattacharya, CEO, will present at the H.C. Wainwright Global Investment Conference, taking place September 14-16, 2026, at the Lotte New York Palace Hotel in New York, NY.
Presentation Details:
Format: Corporate Presentation
Presenter: Sulagna Bhattacharya, CEO
Date & Time: Monday, September 14, 2026, 1:00 PM ET
Members of the management team will also be available for one-on-one meetings with institutional investors during the conference. Investors interested in scheduling a meeting should contact an H.C. Wainwright representative or reach out to Nanoscope directly.
About MOGENRY (sonpiretigene isteparvovec; MCO-010)
Nanoscope’s multi-characteristic opsin (MCO) technology utilizes a proprietary genetically engineered synthetic opsin to enable optimized performance in terms of high light sensitivity across a broad spectrum and fast kinetics. After Nanoscope’s Co-Founder, President, and Chief Scientific Officer, Samarendra Mohanty, envisioned and invented the technology, his team has spent over a decade evaluating its performance across multiple animal models and human diseases. MOGENRY is an investigational, one-time, in-office, intravitreal optogenetic gene therapy built on Nanoscope’s MCO platform. By delivering a multi-characteristic opsin gene to the highly dense bipolar retinal cells, MOGENRY makes these surviving cells directly light-sensitive, enabling them to utilize the remaining visual circuitry following photoreceptor loss. MOGENRY does not require genetic testing, invasive surgery, or repeat dosing, and is designed for administration within existing retina office workflows.
About Nanoscope Therapeutics
Nanoscope Therapeutics is developing disease-agnostic, vision-restoring optogenetic therapy for millions of patients blinded by retinal degenerative diseases. Following positive results from the RESTORE Phase 2b/3 multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the FDA has accepted and filed the Company’s BLA for MOGENRY. If approved, MOGENRY has the potential to become the standard of care for patients with RP, administered as a one-time, in-office injection without the need for genetic testing. The Company has also shown promising results in the STARLIGHT Phase 2 clinical trial of MCO-010 in Stargardt disease (SD) (NCT05417126) and plans to initiate a Phase 3 registrational trial in 2026. MCO-010 has received FDA Fast Track and Orphan Drug designations for both RP and SD, along with RMAT designation for SD, and EMA Orphan designations covering non-syndromic and syndromic rod- and cone-dominant dystrophies, as well as macular dystrophies. MCO-010 has also received Sakigake and Orphan designations for inherited retinal dystrophies (IRDs) in Japan and an Orphan designation for IRDs in Saudi Arabia. A Phase 2 program for MCO in geographic atrophy is expected to start in 2026, and other IND-ready programs include Leber congenital amaurosis (LCA).
Contact:
Nanoscope Therapeutics, Inc.
(817) 857-1186
View original content to download multimedia:https://www.prnewswire.com/news-releases/nanoscope-therapeutics-to-participate-in-the-28th-annual-hc-wainwright-global-investment-conference-302876148.html
SOURCE Nanoscope Therapeutics
